In the phase II study of osimertinib for EGFR-TKI naïve patients with uncommon EGFR mutation-positive NSCLC (KCSG-LU15-09), 22 of the 36 patients received osimertinib as the 1L treatment [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.